PRME - Prime Medicine, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$7.00
DETAILS
HIGH:
$8.00
LOW:
$6.00
MEDIAN:
$7.00
CONSENSUS:
$7.00
UPSIDE:
59.27%
About Prime Medicine, Inc. (https://www.primemedicine.com)
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Allan Reine | Chief Executive Officer & Director | 1975 | $1,065,389 USD |
| Keith Michael Gottesdiener | Consultant | 1954 | $1,021,968 USD |
| Svetlana Makhni | Chief Financial Officer | 1984 | $924,027 USD |
| Ann L. Lee | Chief Technical Officer | 1962 | $760,041 USD |
| Matthew J. Hawryluk | Chief Business Officer | 1979 | $680,800 USD |
| Jeffrey D. Marrazzo | Executive Chair | 1979 | $140,161 USD |
| Andrew Anzalone | Co-Founder | 1987 | – |
| David R. Liu | Co-Founder & Member of Scientific Advisory Board | – | – |
| Mohammed Asmal | Chief Medical Officer | – | – |
| Niamh Alix | Chief Human Resources Officer | – | – |
| Ryan E. Brown | Chief Legal Officer | 1979 | – |